Markus Warmuth, M.D. | President and Chief Executive Officer

Yutaka Ishizaka | Senior Vice President, Planning & Operations

Peter Smith, Ph.D. | Vice President, Target Biology

Lihua Yu, Ph.D. | Vice President, Bioinformatics

Andrea Gerken, M.B.A | Associate Director of Business Development

Markus Warmuth, M.D.
President and Chief Executive Officer

Dr. Markus Warmuth joined H3 Biomedicine as Chief Scientific Officer in August 2011 and became President and Chief Executive Officer on October 1, 2011. Markus brings significant experience in cancer biology, drug discovery and clinical oncology to H3. During his career as a pharmaceutical industry research executive, he has successfully built and shaped oncology research groups and portfolios.

Prior to joining H3, Markus was Head of Oncology Drug Discovery for the Novartis Institute for Biomedical Research (NIBR), Cambridge (U.S.) Site. There, he oversaw a significant part of NIBR’s global oncology drug discovery portfolio from target discovery to clinical development.

Markus studied and received his doctorate in medicine from the Ludwig-Maximilians-University of Munich, Germany. He trained in Internal medicine and oncology at the University of Munich. From 1998 to 2002, he had an appointment as a principal scientist with the “Clinical Cooperation Group Signaling” at the German National Research Center of Environment and Health (GSF), where he studied the mechanism of action of and resistance to multiple small molecule kinase inhibitors in leukemia and lymphoma.

From 2002 to April 2008, Markus worked at the Genomics Institute of the Novartis Research Foundation (GNF), San Diego, where he was Director of Kinase Biology, Head of the Oncology Pharmacology Program and a member of GNF’s Research and Drug Discovery Steering Committee.



Yutaka Ishizaka
Senior Vice President, Planning & Operations

Yutaka “Ish” Ishizaka joined H3 Biomedicine as Senior Vice President, Planning & Operations in July 2011. Previously, Ish served as Vice President of Andover Site Operations for Eisai Inc., where he was responsible for leading business planning, operations and legal affairs for Eisai’s largest U.S. R&D site.

Ish has more than 20 years of experience in business operations management, law and project management. While at Eisai he helped to guide the Andover Site’s growth from a mid-sized research laboratory of 50 employees to its current integrated research and development operation of approximately 300 employees. He built the administrative and legal functions in Andover including HR, Finance, IT, Facilities, EH&S, Contracts and IP, and led the development of a new $65 million research facility.

Prior to joining Eisai, Ish was a principal at the consulting firm of Lampert & Associates, a partner at the law firm of Graham & James and an associate at O’Melveny & Myers.

Ish received his J.D. from Columbia University Law School and is a member of the New York and Massachusetts Bar Associations. He earned a B.A. from Trinity College in Hartford, Connecticut.




Peter Smith, Ph.D.

Vice President, Target Biology

Dr. Peter Smith joined H3 Biomedicine in 2011 as the Director of Target Biology and was promoted to Executive Director in 2012. Peter came to H3 from Millennium Pharmaceuticals in Cambridge, MA where he held positions of increasing responsibility in the oncology discovery group.

At Millennium, Peter led discovery and translational research efforts for the first-in-class NEDD8-activating enzyme inhibitor programs currently in clinical trials and he was a key member of the global development teams. His team’s work led to the design of stratified clinical trials and predictive classifiers of response and identified novel mechanisms of resistance. In addition, Peter and his group made key contributions to the drug discovery and translational biology efforts of several targets in the Ubiquitin-Proteasome system, autophagy pathways and mitotic kinases.

Prior to Millennium, Peter served as a post-doctoral researcher at the Dana-Farber Cancer Institute, Harvard Medical School; at the Molecular Medicine Unit, St James’s University Hospital, University of Leeds, U.K.; and at the Cancer Research Unit, University of Newcastle upon Tyne, U.K. He is published in over 30 research journals, including Nature and Cancer Cell, and is named on three patents for his work.

Peter earned a Ph.D. from the Cancer Research Unit at the University of Newcastle upon Tyne, U.K. and a B.S. in pharmacology from the University of Sheffield, U.K. He is a member of the American Association for Cancer Research and the British Association for Cancer Research.



Lihua Yu, Ph.D.

Vice President, Bioinformatics

Dr. Yu has spent more than 17 years in computational biology and bioinformatics, and has deep experience in the area of cancer genomics and predictive biomarkers. Her expertise in demonstrating how bioinformatics supports cancer genomics has enabled her to integrate the discipline into drug discovery and translational science continuums.

Before coming to H3 Biomedicine, Lihua spent 12 years with Astra Zeneca’s Research and Development unit, helping to build and deliver the multinational pharmaceutical company’s oncology bioinformatics capabilities. During her time there, she provided bioinformatics support to key areas of oncology drug discovery programs, including target identification and patient selection initiatives. She also led efforts to leverage public cancer genomic initiatives, such as The Cancer Genome Atlas, to facilitate genetic target identification.

Lihua received a B.E. in biomedical engineering and a B.E. in automation from Tsinghua University in Beijing. She earned her master of engineering from Tsinghua University and a Ph.D. from Boston University. Lihua is a two-time recipient of the AstraZeneca Global Scientific and Technical Achievement Award, and is an active member of the American Association for Cancer Research.



Andrea Gerken, M.B.A
Associate Director of Business Development

Andrea Gerken joined H3 Biomedicine to lead Program and Alliance Management in November 2012. Prior to joining H3, Andrea held the position of Manager of Research Operations in Ophthalmology and prior to that as Alliance Manager in the External Drug Discovery group at Novartis Institutes for BioMedical Research (NIBR). At NIBR she was responsible for strategic planning, research operations and integration activities following the acquisition of Alcon. During her tenure as Alliance Manager, several programs achieved successful clinical milestones for oncology and diabetes indications.

Andrea began her career in industry at Triad Therapeutics and GNF (The Genomics Institute of the Novartis Research Foundation) as a researcher in drug discovery biology. Andrea received her M.B.A. from Columbia Business School and her B.S. degrees in physics and math from the College of Charleston in Charleston, South Carolina.